Osteoarthritis: Wnt inhibitor shows potential as a DMOAD
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Rheumatology"
DOI: 10.1038/nrrheum.2017.164
Abstract: New research demonstrates that SM04690, a small-molecule inhibitor of the Wnt signalling pathway, has potential as a disease-modifying osteoarthritis (OA) drug (DMOAD). “SM04690 was able to induce chondrocyte differentiation and regenerate and protect cartilage both… read more here.
Keywords: inhibitor; wnt; model; dmoad ... See more keywords
The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Rheumatology"
DOI: 10.1038/s41584-018-0010-z
Abstract: Currently, no disease-modifying osteoarthritis drugs (DMOADs) have been approved. Past clinical trials have failed for several reasons, including the commonly applied definition of eligibility based on radiographic assessment of joint structure. In the context of… read more here.
Keywords: role radiography; eligibility; radiography; clinical trials ... See more keywords